A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Stella
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Arkansas Research Trials, North Little Rock, Arkansas
DermDox Centers for Dermatology, Camp Hill, Pennsylvania
University of Pennsylvania, Philadelphia, Pennsylvania